Evidence map›Paper›PMID 39635151›Full record

ArticleRoyal Society open science2024

Optimal COVID-19 vaccine prioritization by age depends critically on inter-group contacts and vaccination rates.

Iker Atienza-Diez, Gabriel Rodriguez-Maroto, Saúl Ares, Susanna Manrubia

Abstract read
In one paragraph

Article in Royal Society open science, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Iker Atienza-Diez *Centro Nacional de Biotecnologia (CNB), CSIC, Grupo Interdisciplinar de Sistemas Complejos (GISC), Madrid, Spain.ORCID https://orcid.org/0000-0001-5941-4775
Gabriel Rodriguez-Maroto *Centro Nacional de Biotecnologia (CNB), CSIC, Grupo Interdisciplinar de Sistemas Complejos (GISC), Madrid, Spain.ORCID https://orcid.org/0000-0001-8926-2709
Saúl AresCentro Nacional de Biotecnologia (CNB), CSIC, Grupo Interdisciplinar de Sistemas Complejos (GISC), Madrid, Spain.ORCID https://orcid.org/0000-0001-6214-4083
Susanna ManrubiaCentro Nacional de Biotecnologia (CNB), CSIC, Grupo Interdisciplinar de Sistemas Complejos (GISC), Madrid, Spain.ORCID https://orcid.org/0000-0003-0134-2785

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The limited availability of COVID-19 vaccines has prompted extensive research on optimal vaccination strategies. Previous studies have considered various non-pharmaceutical interventions, vaccine efficacy and distribution strategies. In this work, we address the combined effects of inter-group contacts and vaccination rates under contact reduction, analysing the Spanish population's demographic and age group contact patterns and incorporating reinfection dynamics. We conduct an exhaustive analysis, evaluating 362 880 permutations of nine age groups across six vaccination rates and two distinct, empirically quantified scenarios for social contacts. Our results show that at intermediate-to-high vaccination rates with unrestricted social contacts, optimal age-based vaccination strategies only slightly deviate from older-to-younger prioritization, yielding marginal reductions in deaths and infections. However, when significant reductions in social contacts are enforced-similar to the lockdowns in 2020-there are substantial improvements, particularly at moderate vaccination rates. These restrictions lead to a transition where infection propagation is halted, a scenario that became achievable during the pandemic with the observed vaccination rates. Our findings emphasize the importance of combining appropriate social contact reductions with vaccination to optimize age-based vaccination strategies, underscoring the complex, nonlinear dynamics involved in pandemic dynamics and the necessity for tailored context-specific interventions.

Indexed as

compartmental modelcontact matrixinhibition of epidemic propagationSpanish demographic structurevaccine rollout

Identifiers

PMID39635151
PMCPMC11615194

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.